Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)

A combination of 5‐fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC‐BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P < 0.01). Estimated 2‐year survival rate from first recurrence was 85% for the FAC‐BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease‐free interval from the first recurrence, but additional follow‐up is needed to determine its effect on long‐term survival.